Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SANCTUARY: Amrubicin plus nintedanib in previously treated small-cell lung cancer with idiopathic pulmonary fibrosis
jRCTs061260038Recruiting
- Start
- Jul 2026
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of amrubicin and nintedanib in small cell lung cancer (SCLC) and idiopathic pulmonary fibrosis (IPF). Primary endpoint: Incidence of pneumonitis. Started Jul 2026; status: recruiting.
02
Drugs
amrubicinnintedanib
03
Conditions
small cell lung cancer (SCLC)idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on jRCTs061260038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061260038.